Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Nalmefene is an orally administered competitive opioid receptor antagonist targeted at reducing alcohol consumption in alcohol-dependent patients. As part of the regulatory requirements for drug approval, the potential of novel compounds for causing unwanted proarrhythmia should be studied in a thoroughly designed clinical QT/corrected QT (QTc) study (International Conference on Harmonisation [ICH] E14 guideline).
Originalsprog | Engelsk |
---|---|
Tidsskrift | Clinical Drug Investigation |
Vol/bind | 31 |
Udgave nummer | 11 |
Sider (fra-til) | 799-811 |
Antal sider | 13 |
ISSN | 1173-2563 |
DOI | |
Status | Udgivet - 2011 |
ID: 48052162